Study characteristics: cohort studies and case series
| Author, year (design) | Intervention and patients (N) | Age and sex | Study duration/treatment observation period | Setting | Patient characteristics | Concomitant sedatives, analgesics |
|---|---|---|---|---|---|---|
| Alexopoulou et al,32 2014 (cohort with crossover) | Dexmedetomidine iv infusion (n=13) | 62 (55–69) years* 77% male | 57 hours/9 hours | Critical care unit | Mechanically ventilated ICU patients | None reported |
| No treatment (n=13) | ||||||
| Kim et al,39 2014 (case series) | Midazolam iv infusion (n=5) | 67 (40.5–72) years* 80% male | 24 hours/24 hours | Critical care unit | Mechanically ventilated ICU patients requiring continuous sedation | None reported |
| Oto et al,40 2012 (case series) | Dexmedetomidine iv infusion (n=10) | 68±9 years† 30% male | 24 hours/9 hours | Critical care unit | Mechanically ventilated ICU patients requiring iv sedation | None reported |
| Hardin et al,33 2006 (cohort) | Lorazepam iv (intermittent sedation) (n=6) | 58.5±9.8 years† 17% male | 24 hours/24 hours | Critical care unit | Mechanically ventilated ICU patients | None reported |
| Lorazepam iv (continuous sedation) (n=6) | 43.2±13 years† 33% male | |||||
| Lorazepam iv (continuous sedation with neuromuscular blockade) (n=6) | 61.3±8.8 years† 83% male |
ICU, intensive care unit; iv, intravenous.
*Data presented as median (range).
†Data presented as mean±standard deviation.